Meir Panim implements programs that serve Israel’s neediest populations with respect and dignity. Meir Panim also coordinated care packages for families in the South during the Gaza War.
Japan’s largest pharmaceutical company, Takeda, recently signed an agreement with Teva Pharmaceutical Industries to commercialize the Israeli company’s innovative treatment for Parkinson’s disease, rasagiline, in Japan.
The rasagiline tablets, which are approved in over 40 countries for the treatment of Parkinson’s disease, gained UK and EU-marketing authorization in 2005 and US FDA approval in 2006.
“It is estimated there are about 150,000-180,000 people diagnosed with Parkinson’s disease in Japan, many of whom are waiting for a new treatment option,” said Nancy Joseph-Ridge, M.D., General Manager of Takeda’s Pharmaceutical Development Division located in Osaka, Japan in a press release on April 27.
“We will continue working on the development in cooperation with Teva so that we can bring this medicine to Japanese patients as quickly as possible,” Joseph-Ridge said.
“This agreement represents Teva’s continued commitment to introducing our innovative medicines to patients in Japan,” added Teva Global R&D president and Chief Scientific Officer, Dr. Michael Hayden.
Teva and Takeda entered an agreement in December 2013 to develop glatiramer acetate for the treatment of multiple sclerosis.
Developed by Teva, rasagiline was initially discovered by two Haifa Technion professors, John Finberg and Moussa Youdim, who were instrumental in the early clinical development of the anti-Parkinson drug.
Parkinson’s disease is a degenerative disorder of the central nervous system, whose symptoms include shaking, rigidity, slowness of movement and difficultly with walking as well as dementia in advanced stages. An estimated seven to 10 million people suffer from the disease across the world according to the Parkinson’s Disease Foundation.
According to Teva’s website, rasagiline is a monoaxmine oxidase B (MAO-B) inhibitor that increases available synaptic dopamine in the brain, which might improve the motor symptoms characteristic of Parkinson’s, slowing the progression of the disease.
“Rasagiline has an established safety and efficacy profile…[it] will be an important product for Japan, where the number of available treatment options for Parkinson’s disease remains limited,” said Dr. Hayden.
About the Author: Anav Silverman is a regular contributor to Tazpit News Agency.
If you don't see your comment after publishing it, refresh the page.
Comments are closed.
Israeli military is watching the northern border closely, waiting for the day the “changes” arrive. Rebels already control Syria’s side of the fence.
Canada will strip citizenship from those who travel abroad to join ISIS or other terrorist groups.
An Arab media outlet appears to be having issues with the closure of the Cave of the Patriarchs to Muslims over Rosh Hashana.
Nearly 70 years after the Nazis fell, evidence is found in Theresienstadt that life flourished even among those marked for death.
There are IDF officers whose job is to oversee all operations and endeavor to ensure the civilian population is protected.
The Cabinet has approved a massive infrastructure upgrade of Sderot and other southern Israeli communities.
Yemen, where the ‘Arab Spring’ begun, continues to be mired in turmoil and terror.
Cease-fire negotiations in Cairo between Israel and Gaza terrorist factions are being held Tuesday in deference to Rosh Hashana.
President Reuven Rivlin is set to inaugurate the Jewish Museum of Warsaw when he travels to Poland in October.
Angry parents spoke out Sunday against Arabs attacking their children on the Mount of Olives.
Only 30 % of European Jews will attend high holiday services; 1/4 fear wearing Jewish symbols.
It’s not monopoly money. It’s Israel’s new 50 Shekel bill (in the middle), with a picture of poet Shaul Tchernikovsky on it. The bill is said to feature some of the most advanced anti-counterfeiting technologies, and it just went into circulation.
S&P has confirmed that Israel’s credit rating is good, and we’re still on the right fiscal path.
Gush Etzion residents were surprised and angry when the issue of the fence was raised from the dead.
An airlift of 21 flights from El- Al Airlines flying from 10 different international locations, are bringing parents of lone soldiers serving in the IDF to Israel.
A memorial event with a special photo exhibition honoring the late Israeli Prime Minister Ariel Sharon took place on Monday.
China’s Yuanda Enterprise Group announced last week that it had bought the Israeli company AutoAgronome Israel Ltd for $20 million in order to expand its business to high-tech agriculture.
Jerusalem district firefighters and rescue volunteers, alongside U.S. Marines and families of 9/11 victims, marked the 13th anniversary 9/11 in a special ceremony held in the Jerusalem Hills.
Ashdod residents witnessed the test operation, which simulated a rocket attack from Iran on southern Israel.
Israel is sharing its knowledge in the fields of public health in coordination with the World Health Organization’s efforts to stop the Ebola Virus Disease
Printed from: http://www.jewishpress.com/news/breaking-news/tevas-parkinson-drug-now-marketed-in-japan/2014/05/29/
Scan this QR code to visit this page online: